$67 Million


Follow-on Offering

Bookrunner, July 2015

NeuroDerm is clinical stage pharmaceutical company developing treatments for CNS disorders through proprietary reformulations of existing drugs. The Company’s product candidates are based on patented reformulations of approved drugs, which may qualifies them for an accelerated, lower risk regulatory pathway to marketing approval. The Company has two lead products for Parkinson’s disease, ND0612H and ND0612L, which are liquid formulations of levodopa (LD) and carbidopa (CD) being developed for severe and moderate Parkinson’s disease, respectively